Cambridge Brain Mets Trial 1: A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low dose, targeted radiotherapy

Trial Profile

Cambridge Brain Mets Trial 1: A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low dose, targeted radiotherapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Advanced breast cancer; Brain metastases; Lung cancer; Male breast cancer
  • Focus Pharmacokinetics; Proof of concept
  • Acronyms CamBMT1
  • Most Recent Events

    • 02 Jun 2017 Phase I results of CamBMT1 trial (n=10) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
    • 12 Dec 2015 Accrual to date is 10% according to Unite.d Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top